Kyeong Uoon Kim1. 1. Author Affiliation: Department of Public Health, Korea University, Seoul, Republic of Korea.
Abstract
BACKGROUND: Cancer is the leading cause of death in Korean adults. A good quality of life for patients at end life can control pain and symptoms and help maintain well-being. OBJECTIVE: The aim of this study was to measure quality of life in end-stage cancer patients using the Korean version of the McMaster Quality of Life (K-MQOL). METHODS: The K-MQOL was administered to adult end-stage cancer patients from 4 Korean university hospitals. We hypothesized quality-of-life differences between participants by daily activity level, number of symptoms, and participant status (alive or not) at end of study. RESULTS: Participants' mean age was 49.2 years, and 74.5% were men. As hypothesized for discriminant validity, Pearson correlation coefficients among the K-MQOL were less than 0.4, with the exceptions of emotion (0.25-0.52) and cognition (0.33-0.51). A higher Eastern Cooperative Oncology Group Performance States Rating score was significantly associated with a lower quality of life (F = 2.840, P = 0.034). The mean score of those within 21 days of death was significantly lower than that of patients who were alive at the end of the study (t = -2.48, P = .04). Patients with a smaller number of symptoms other than pain had significantly higher quality-of-life scores than did those with more symptoms (F = 5.059, P = .004). CONCLUSIONS: The K-MQOL provided reliable and valid scores of quality of life in end-stage cancer patients. IMPLICATIONS FOR PRACTICE: Assessing end-stage cancer patients' quality of life helps to identify each patient's condition and aspects that could benefit from nursing care. We anticipate that the K-MQOL will be useful for patient assessment in clinical and community settings.
BACKGROUND:Cancer is the leading cause of death in Korean adults. A good quality of life for patients at end life can control pain and symptoms and help maintain well-being. OBJECTIVE: The aim of this study was to measure quality of life in end-stage cancerpatients using the Korean version of the McMaster Quality of Life (K-MQOL). METHODS: The K-MQOL was administered to adult end-stage cancerpatients from 4 Korean university hospitals. We hypothesized quality-of-life differences between participants by daily activity level, number of symptoms, and participant status (alive or not) at end of study. RESULTS:Participants' mean age was 49.2 years, and 74.5% were men. As hypothesized for discriminant validity, Pearson correlation coefficients among the K-MQOL were less than 0.4, with the exceptions of emotion (0.25-0.52) and cognition (0.33-0.51). A higher Eastern Cooperative Oncology Group Performance States Rating score was significantly associated with a lower quality of life (F = 2.840, P = 0.034). The mean score of those within 21 days of death was significantly lower than that of patients who were alive at the end of the study (t = -2.48, P = .04). Patients with a smaller number of symptoms other than pain had significantly higher quality-of-life scores than did those with more symptoms (F = 5.059, P = .004). CONCLUSIONS: The K-MQOL provided reliable and valid scores of quality of life in end-stage cancerpatients. IMPLICATIONS FOR PRACTICE: Assessing end-stage cancerpatients' quality of life helps to identify each patient's condition and aspects that could benefit from nursing care. We anticipate that the K-MQOL will be useful for patient assessment in clinical and community settings.